Entasis Therapeutics Holdings (ETTX) Receives a Buy from H.C. Wainwright


H.C. Wainwright analyst Ed Arce maintained a Buy rating on Entasis Therapeutics Holdings (ETTX) today and set a price target of $18.00. The company’s shares closed last Monday at $5.03.

According to TipRanks.com, Arce is a 4-star analyst with an average return of 6.3% and a 35.3% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Conatus Pharmaceuticals, and Aurinia Pharmaceuticals.

Currently, the analyst consensus on Entasis Therapeutics Holdings is a Moderate Buy with an average price target of $18.00.

See today’s analyst top recommended stocks >>

The company has a one-year high of $9.25 and a one-year low of $3.97. Currently, Entasis Therapeutics Holdings has an average volume of 16.21K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts